Nancy L. Reaven, MA

This commentary addresses the possible reasons for treatment gaps between recommended therapy for patients with CKD, and the realities of current practices, and examines new developments that may bridge the gap.

A budget-impact model illustrates the economic outcomes associated with renoprotective therapy on privately insured patients with advanced kidney disease.